Ovarian carcinoma in children with constitutional mutation of SMARCA4: single-family report and literature review

Agata Pastorczak1 · Karolina Krajewska1 · Zuzanna Urbanska1 · Bartosz Szmyd1 · Elzbieta Salacinska-Los2 · Józef Kobos3 · Wojciech Mlynarski1 · Joanna Trelinska1

Received: 30 September 2020 / Accepted: 15 April 2021 / Published online: 28 April 2021
© The Author(s) 2021

Abstract

Ovarian carcinoma is an extremely rare malignancy in children, often developing on the underlying inherited background. Female carriers of pathogenic germline mutations of SMARCA4 are at risk of an aggressive type of undifferentiated ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Regardless of age of the patient, stage of the disease, and oncological treatment, the prognosis for SCCOHT is poor. Therefore, early intervention with risk-reducing surgeries is recommended for these patients. In this study, we report genetic testing of a family with two children carrying pathogenic germline mutations of SMARCA4 and summarize the course of SCCOHT in all pediatric patients reported in the literature with constitutional defects identified within the SMARCA4 locus.

Keywords Ovarian carcinoma · Children · Genetic predisposition · SMARCA4

Introduction

Pediatric ovarian neoplasms are rare tumors with a reported incidence of 2.6 per 100,000 girls [1]. Unlike in adult women, in whom epithelial carcinomas account for 90% of ovarian malignancies, germ cell tumors (GCTs) predominate in children [2]. Due to favorable histology of childhood ovarian tumors, pediatric patients exhibit an excellent 10-year survival rate of 85% [2]. However, some children (less than 5% of cases) develop tumors of epithelial origin, including also an extremely aggressive type of undifferentiated ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) [1]. This neoplasm displays histopathological similarities to malignant rhabdoid tumors and is driven by somatic (57%) and/or germline (43%) inactivating mutations of the SMARCA4 gene [3]. The SMARCA4 protein, which has helicase and ATPase functions, is a component of the ATP-dependent chromatin remodeling complex SNF/SWI, which is required for transcriptional activation of genes [4]. A particularly high rate of constitutional heterozygous mutations of SMARCA4 is seen in pediatric patients who develop SCCOHT [3, 5–10]. These children are diagnosed with autosomal dominant rhabdoid tumor predisposition syndrome type 2 (RTPS2; OMIM #613325)[11], in which other malignant lesions are formed in the brain, spine, lung, bladder, pelvis, and kidney [12, 13]. Considering the rarity and poor prognosis of SCCOHT in children and the necessity for genetic counseling of affected families, we undertook this study on an affected family. In this study, we describe a family with two children that were carrying germline pathogenic mutations of SMARCA4, which encodes the BRG1 protein. One of them developed fatal ovarian carcinoma. Additionally, we summarize the course of SCCOHT in all pediatric patients with constitutional defects identified in the SMARCA4 gene, as reported in the literature.

Methods

Written informed consent for research was obtained from the patient’s parents. The study was approved by the Medical University of Lodz Review Board (No. RNN/108/18/
Results

Family report

The proband, a fourteen-year-old girl, was admitted to the hospital due to weakness, weight loss with accompanying abdominal distention, and a palpable tumor in the hypogastrium. Serum alpha fetoprotein (AFP) and beta human chorionic gonadotropin (β-hCG) levels of the patient were normal, but cancer antigen 125 (CA-125) level was increased 40-fold. Magnetic resonance imaging revealed the presence of a tumor in the pelvis, which arose from the right ovary and exhibited dimensions of 16 × 14 × 11 cm along with ascites. There was no evidence of distant metastases. The histopathological results of the surgical biopsy indicated the presence of a large cell endocrine carcinoma that was part of the teratoma. Histopathological examination indicated the presence of small nests, cords, and trabeculae of neoplastic cells with scant eosinophilic cytoplasm and hyperchromatic nuclei (Fig. 1e). The patient received three courses of chemotherapy according to the TGM 95 protocol (VIP cycle: etoposide, ifosfamide, cisplatin) followed by macroscopic radical surgical removal of the residual mass and two postoperative VIP courses. Disease recurrence was noted one month later, when the patient underwent emergency operation because of suspected mesenteric torsion. At that time, two tumors in the pelvis and abdomen as well as massive neoplastic infiltration of the peritoneum were observed. After using extended panel of immunohistochemical staining tumor cells showed the following pattern of expression: vimentin (+), synaptophysin (+), MCA (+), EMA (+), INI-1 (+), CD56 (+), β-catenin (+), NSE (+), SMA (+), CD30 (−), LCA (−), AFP (−), CD117 (−), CD10 (−), S-100 (−), CD99 (−), CD68 (−), and desmin (−). The histopathological image and immunohistochemical stains were the most consistent with neuroendocrine carcinoma or a poorly differentiated neuroendocrine tumor. After receiving 1 cycle of chemotherapy (bleomycin, carboplatin, doxorubicin) followed by peritoneal drainage, no significant reduction in tumor size was seen. Due to massive peritoneal carcinomatosis, palliative care was administered. The patient died 8 months after the initial diagnosis of ovarian tumor.

The family history of the patient was examined, and a paternal grandmother and her sister who underwent panhysterectomy and salpingo-oophorectomy at the age of 34 and 49 years, respectively, were identified. Two other paternal aunts were diagnosed with breast cancer at the age of 51 and 60 years, respectively. A paternal uncle was diagnosed at the age of 34 years with lymphoma and secondary leukemia, and a paternal great grandfather developed prostate cancer (Fig. 1a).

The proband’s diagnosis was based on histopathological analysis, whereas other oncological diagnoses in her family were based on self-reporting by the proband’s mother.

Since such a rare, atypical histopathology of the tumor, accompanied by an aggressive course of the disease in the proband, was observed and the family history suggested more than one cancer predisposition gene, cancer gene panel testing was recommended for the patient (Supplementary Table S1). A pathogenic nonsense variant within exon 24 of SMARCA4 gene (NM_001128849.3):c.3310C > T, p. Gln1104Ter) was identified in the heterozygous form in the proband. This mutation was also seen in the father (Fig. 1b) and the thirteen-year-old asymptomatic sister. Microarray analysis of the somatic tumor tissue revealed a 21.185 kbp loss of heterozygosity (LOH) within the 19p12-p13.3 region (260912_22445808), which encompasses 692 genes including SMARCA4 (Fig. 1c). Immunohistochemistry demonstrated complete loss of BRG1 expression in 80% of cancer cells within the tumor (Fig. 1d).

According to the will of the parents increased surveillance for the detection of early cancer using both biomarkers and sonography, every three months was applied in unaffected sister. Parents were informed about the limitations of such approach and the benefits of possible prophylactic bilateral oophorectomy preceded by the oocyte cryopreservation when the girl reaches puberty. Psychological support was offered to the family during the illness of the first child and after the genetic background of cancer was identified in the family members.

Clinical phenotype of pediatric patients with germline mutation of SMARCA4

We analyzed the clinical phenotypes and genotypes of all the pediatric patients with confirmed germline mutation of SMARCA4 reported in the literature and identified thirteen such cases (Table 1) [3, 6, 7, 9, 10, 14–16]. Nine of them
Ovarian carcinoma in children with constitutional mutation of SMARCA4: single-family report...

Fig. 1 Genetic testing of the proband’s family. a A pedigree of the proband’s family. The proband with SCCOHT had a germline mutation in exon 24 of the SMARCA4 gene (c.3310C>T) inherited from her father. This mutation was also identified in the proband’s sister. (+) denotes heterozygous mutation carrier in the germline; (−) denotes wild type in the germline. NOS denotes not otherwise specified. A diagonal line through a symbol indicates that the person is deceased. b Chromatograms of germline and somatic SMARCA4 mutations in the proband and proband’s parents. c Results of single-nucleotide polymorphism array analysis of the tumor genome in the patient with germline SMARCA4 mutation; Chromosome plot displays the presence of a loss of heterozygosity (LOH) at the 19p12-p13.3 region encompassing the SMARCA4. d Immunohistochemical staining of ovarian carcinoma using antibodies against BRG1 (100x). Loss of BRG1 expression was observed in 80% of cancer cells in the tumor. e Hematoxylin–eosin staining of ovarian carcinoma of the proband (400x)
| n | Age at cancer diagnosis | SMARCA4 (NM_001128849) germline mutation | Mutation type | SMARCA4 somatic mutation/LOH | Serum CA-125 | Stage at diagnosis | Hypercalcemia at diagnosis | Family history of cancer | Treatment | Outcome | Source |
|---|------------------------|------------------------------------------|--------------|-------------------------------|--------------|-------------------|--------------------------|---------------------------|----------------|---------|--------|
| 1 | 13                     | c.2935C>T, p.Arg979*                     | Nonsense     | c.1236delC, p.Gln413Argfs*88 | ND           | IIIc             | Present                  | No                        | ND             | in CR at 2 years from diagnosis | [14]   |
| 2 | 12                     | c.898C>T, p.Gln300Ter                    | Nonsense     | c.3215 + 1G > A              | ND           | ND               | ND                       | ND                        | ND             | ND      | [6]    |
| 3 | 15                     | c.300delAG, p.Gly102Ter                  | Nonsense     | LOH                          | Increased    | IV               | PRESENT                  | ND                        | PAVEP-CARBOPEC regimen | Deceased | [7]    |
| 4 | 12                     | c.2617-3C>G                               | Splice-site  | LOH                          | Increased    | ND               | PRESENT                  | fatal SCCOHT in 24 ys. old mother and her 26 ys. old sister | PEB + RT | in CR at 3 years from diagnosis | [10]   |
| 5 | 11                     | c.4071+1G>A                              | Splice-site  | LOH                          | Slightly increased | Ic | present | fatal SCCOHT in 23 years old mother |
| 6 | 15                     | c.643C>T, p.Gln215*                      | Nonsense     | c.1687_1700del, p.Asn563GlyfsTer83 | Normal       | III              | absent                  | Yolk sac tumor in mother at the age of 16 ys |
| 7 | 13                     | c.3293G>A, p.Gly1080Asp                  | Missense     | c.1326delC, p.Ser442Argfs*59 | Increased    | I                | present                  | No                        | 6 cycles of XC in CR at 1 years from diagnosis | [3]    |
| 8 | 7                      | c.1141C>T, p.Arg381*                     | nonsense     | LOH                          | ND           | IIc              | ND                       | ND                        | Deceased | [3]    |
| 9 | 18                     | c.2932C>T, p.Arg978*                     | Nonsense     | LOH                          | ND           | Ic               | ND                       | ND                        | Deceased | [3]    |
| 10| 9                      | c.2935C>T, p.Arg979*                     | Nonsense     | ND                           | ND           | IA               | present                  | ND                        | ND          | ND      | [15]   |
| 11| 10                     | c.722_735delGTC CCGGCCGCA, p.Gly241fs    | Frameshift   | Homozygous c.722_735delGTC CCGGCCGCA, p.Gly241fs | ND           | IIIC             | present                  | ND                        | ND          | ND      | [15]   |
| 12| 12                     | c.1141C>T, p.Arg381Ter                   | Nonsense     | LOH                          | Increased    | ND               | absent                   | ND                        | EIP, followed by XCV, and + autoSCT | Deceased | 5 months from diagnosis | [16]   |
carried constitutional nonsense mutations of SMARCA4, and LOH at 19p13.2 within the SMARCA4 locus was found in somatic tissue in the majority of malignancies. Patients developed SCCOHT at a median age of 12 (10.5–14.5) years. Half of them showed hypercalcemia and increased serum levels of CA-125. Four patients had a family history of ovarian tumors in women below the age of 35 years. The therapeutic approaches used differed between patients and included chemotherapy, radiotherapy, and stem cell transplantation (in one case). Six out of thirteen patients died due to disease progression and one patient experienced fatal toxic complications after autologous bone marrow transplant [16].

**Discussion**

Pediatric ovarian neoplasms occur very rarely. However, in such cases, cancer predisposition syndromes should be considered, even if the tumor is not of epithelial origin. Several genetic disorders, including DICER1 syndrome, Peutz–Jeghers syndrome, Ollier disease, Maffucci syndrome, and WT-1 related syndromes, are associated with an increased risk for germ cell tumors in children [1]. However, the identification of such disorders does not necessarily affect the treatment and surveillance of patients and family members. In contrast, the diagnosis of RTPS2 in a child with ovarian cancer is essential for appropriate clinical management and genetic counseling [17].

RTPS2 is an autosomal dominant genetic disorder that predisposes infants and children below three years of age to extremely aggressive malignant tumors [17]. It is caused by a germline mutation of SMARCA4, which acts like a tumor suppressor gene. Most of the reported individuals diagnosed with SMARCA4-related RTPS inherited a pathogenic variant of this gene from an unaffected parent. The penetrance appears to be incomplete, and the types of RTPS-related tumors differ between members of the same family [13, 17]. Although SMARCA4 mutations are less penetrant for atypical teratoid rhabdoid tumor than SMARCB1, SCCOHT was exclusively observed in patients constitutionally carrying the deleterious variant of SMARCA4 [12]. In pediatric patients who developed SCCOHT, a family history of ovarian neoplasms at a young age and dismal outcomes were frequently observed.

SCCOHT is usually diagnosed in young women in the second or third decade of life [6]. In pediatric population, this tumor develops mainly in adolescents but individuals diagnosed below the age of 10 years have been also reported [6] [18]. Only 20% of pediatric ovarian cancers are of epithelial origin, and these exhibit a predominance of serous and mucinous histology [1]. SCCOHT is the rarest type in this group, and it is caused by somatic and/or
germline SMARCA4 mutations [19]. In this type, cancer cells resemble rhabdomyoblasts, which are small and round with hyperchromatic nuclei and are immunohistochemically characterized by the increased expression of vimentin, epithelial membrane antigen, and cytokeratins, as well as by the loss of BRG1 protein expression [20]. Additionally, 62% of adult patients and a similar percentage of children exhibit hypercalcemia when diagnosed with SCCOHT [6]. Usually, genetic testing is recommended when ovarian neoplasm with such characteristics is diagnosed in a child and it is eventually followed by the diagnosis of RTPS2.

SCCOHT is refractory to conventional oncological treatment in 75% of patients regardless of the patient’s age or stage of the disease, and median survival time does not exceed fifteen months. Despite individualized and diverse approaches for treatment, recurrence and progression of cancer have been observed in children diagnosed with SCCOHT. Novel therapies targeting the SCCOHT vulnerabilities [such as EZH2 and HDAC, bromodomain and extra-terminal motif containing protein inhibitors (BETi), tyrosine kinase, and PD-1 inhibitors] have been successfully tested, mainly in preclinical studies, but prospective multicenter protocols are highly needed in this particularly rare disease [18]. To this purpose, in 2018, the International SCCOHT Consortium was formed. It aims to explore the biology of SCCOHT in order to discover new targeted therapy and to identify an effective screening procedure among SMARCA4 mutation carriers (https://www.smallcellovarian.org/consortium.html).

In the family examined in the present study, parents were offered genetic testing for their child because of the unusual histopathology of the tumor and a family history that indicated an inherited cancer predisposition. Although the profile of malignancies and age at onset among family members partly matched the phenotype of BRCA1- and BRCA2-associated hereditary breast and ovarian cancer, diagnosis of ovarian neoplasm in the proband at an early age, undifferentiated structure of the tumor, and expression of neuroendocrine markers were characteristic for this type of cancer. Histopathological analysis revealed a large cell endocrine carcinoma that was a part of the teratoma, but the clinical course of the disease was atypical for a GCT. While both the serum markers, AFP and β-hCG, were not elevated, CA-125 levels were increased. Such a profile is indicative of epithelial ovarian cancers rather than GCT [21]. Additionally, cancer remission was short-lived, and recurrence was noted one month after the chemotherapy was completed. Although the patient showed a partial response after first-line platinum-based chemotherapy, which enabled the surgical removal of the residual mass, second-line chemotherapy was completely ineffective. Poor outcome in this patient is consistent with those of pediatric patients with germline mutations of SMARCA4 that were previously described in the literature (Table 1). Recent studies have demonstrated that a combination of surgery, radiotherapy, and high-dose chemotherapy with stem cell rescue could be an effective approach for treating SCCOHT [22]. The administration of such aggressive treatments can only be justified by proper histopathological diagnosis[17]. However, pathologists often struggle with these tumors due to overlapping morphology and immunohistochemistry in this group of cancers [18].

Dismal outcome of pediatric SCCOHT raises questions regarding the optimal timing for genetic testing and early interventions with risk-reducing surgeries. Parents of an unaffected child from the described family decided for increased surveillance for detection of early cancer. However, neither biomarker nor sonography is an effective method for early diagnosis of ovarian cancer. Considering extremely aggressive course and high lethality of SCCOHT, SMARCA4 mutation carriers must be counseled about prophylactic bilateral oophorectomy. There are no official recommendations regarding the age of genetic testing and prophylactic salpingo-oophorectomies for females carrying the pathogenic variant of SMARCA4. Prophylactic bilateral salpingo-oophorectomy in 13-year-old healthy carrier of germline SMARCA4 mutation has been reported. In this case, histopathological examination of the ovaries and tubes, which were serially sectioned, revealed lack of malignant transformation [23]. Podwika et al. argued that, similar to the strategy applied to patients with Li-Fraumeni syndrome (germline TP53 mutation) and Swyer syndrome (46, XY, gonadal dysgenesis), genetic testing should be initiated below the age of 18 years, preferably between the ages of 9 and 15 years [19]. This approach will enable early surgical intervention and allow preservation of fertility in the form of assisted reproductive technology. For female carriers of deleterious SMARCA4, all experts recommend bilateral salpingo-oophorectomy outside the pediatric age range and after completion of puberty, along with regular screening using abdominal ultrasound every six months during childhood [17, 19]. However, due to exceedingly poor outcome of the disease and lack of an effective screening strategy, prophylactic surgery in children below 18 years may be considered if the patient and the family express a strong desire to prevent cancer by surgical removal of the ovaries and tubes. Since the median age at cancer diagnosis in SMARCA4 mutation carriers is lower as compared to BRCA1/BRCA2 mutation carriers, the prophylactic surgery should be offered at least earlier, preferably below the age of 22. At that age, most of the patients do not consider conception yet. Therefore, the oocyte cryopreservation for in vitro fertilization accompanied by pre-implantation genetic testing which will prevent the transmission of pathogenic variant should be recommended as a complementary procedure to invasive surgery. However, genetic testing and prophylactic surgery in at-risk families should be preceded by consent.
and assent procedures that enable family members to estimate the risks and benefits of these tests and surgeries.

Conclusions

SCOCHT is a rare tumor in pediatric population characterized by extremely poor outcome and frequent inherited background. Awareness of the disease should increase since proper pathological diagnosis and age-assisted decision-making regarding an optimal treatment approach are challenging.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10689-021-00258-w.

Author contributions AP involved in concept, interpretation, manuscript draft, and final approval; KK performed study execution, manuscript revision, and final approval; ZU and BS contributed to study execution, interpretation, manuscript revision, and final approval; JK involved in study execution and final approval; WM contributed to manuscript revision and final approval; and JT took part in concept, manuscript revision, interpretation, and final approval.

Funding None.

Data availability If requested.

Declarations

Conflicts of interest All authors declare no competing interests.

Consent to participate Written informed consent for research was obtained from family members.

Ethics approval The study was approved by the Medical University of Lodz Review Board (No. RNN/108/18/KE) and was performed in accordance with the Helsinki Declaration of 1975, as revised in 2000.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Lala SV, Strubel N (2019) Ovarian neoplasms of childhood. Pediat Radiol 49(11):1463–1475. https://doi.org/10.1007/s00247-019-04456-8
2. Lockley M, Stoneham SJ, Olson TA (2019) Ovarian cancer in adolescents and young adults. Pediat Blood Cancer 66(3):e27512. https://doi.org/10.1002/pbc.27512
3. Witkowski L, Carrot-Zhang J, Albrecht S et al (2014) Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet 46(5):438–443. https://doi.org/10.1038/ng.2931
4. Stanton BZ, Hodges C, Calarco JP et al (2017) SMARCA4 ATPase mutations disrupt direct eviction of PRC1 from chromatin. Nat Genet 49(2):282–288. https://doi.org/10.1038/ng.3735
5. Bailey S, Murray MJ, Witkowski L et al (2015) Biallelic somatic SMARCA4 mutations in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Pediat Blood Cancer 62(4):728–730. https://doi.org/10.1002/pbc.25279
6. Connor YD, Miao D, Lin DI et al (2020) Germline mutations of <em>SMARCA4</em> in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: clinical features of a single family and comparison of large cohorts. Gynecol Oncol 157(1):106–114. https://doi.org/10.1016/j.ygyno.2019.10.031
7. Lavrut P-M, Le Loarer F, Normand C et al (2016) Small Cell carcinoma of the ovary, hypercalcemic type: report of a bilateral case in a teenager associated with SMARCA4 germline mutation. Pediatr Dev Pathol 19(1):56–60. https://doi.org/10.2350/15-04-1624-cr.1
8. Moe-Sosnowska J, Szafron L, Nowakowska D et al (2015) Germline SMARCA4 mutations in patients with ovarian small cell carcinoma of hypercalcemic type. Orphanet J Rare Dis 10:32. https://doi.org/10.1186/s13023-015-0247-4
9. McDonald JM, Karakabatsian RG, Pierce HH et al (2012) Small cell carcinoma of the ovary of hypercalcemic type: a case report. J Pediat Surg 47(3):588–592. https://doi.org/10.1016/j.jpedsurg.2011.12.004
10. Martinez-Borges AR, Petty JK, Hurt G, Stribing JT, Press JZ, Castellino SM (2009) Familial small cell carcinoma of the ovary. Pediatr Blood Cancer 53(7):1334–1336. https://doi.org/10.1002/pbc.22184
11. Hasselblatt M, Gesk S, Oyen F et al (2011) Nonsense Mutation and Inactivation of SMARCA4 (BRG1) in an Atypical Teratoid/Rhabdoid Tumor Showing Retained SMARCB1 (INI1) Expression. Am J Surg Pathol 35(6):933–935. https://doi.org/10.1097/PAS.0b013e3182196a39
12. Agaimy A, Foulkes WD (2018) Hereditary SWI/SNF complex deficiency syndromes. Semin Diagn Pathol 35(3):193–198. https://doi.org/10.1053/j.sendp.2018.01.002
13. Schneppenheim R, Frühwald MC, Gesk S et al (2010) Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet 86(2):279–284. https://doi.org/10.1016/j.ajhg.2010.01.013
14. Errichiello E, Mustafa N, Vetro A et al (2017) SMARCA4 inactivating mutations cause concomitant Coffin-Siris syndrome, microphthalmia and small-cell carcinoma of the ovary hypercalcemic type. J Pathol 243(1):9–15. https://doi.org/10.1002/path.4926
15. Ramos P, Karnezis AN, Craig DW et al (2014) Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet 46(5):427–429. https://doi.org/10.1038/ng.2928
16. David MP, Venkatramani R, Lopez-Terrada DH, Roy A, Patil N, Fisher KE (2018) Multimodal molecular analysis of an atypical small cell carcinoma of the ovary, hypercalcemic type. J Mol Case Stud. https://doi.org/10.1101/mcs.a002956
17. Foulkes WD, Kamihara J, Evans DGR et al (2017) Cancer surveillance in Gorlin syndrome and rhabdoid tumor predisposition syndrome. Clin Cancer Res 23(12):e62–e67. https://doi.org/10.1158/1078-0432.ccr-17-0595
18. Tischkowitz M, Huang S, Banerjee S et al (2020) Small-cell carcinoma of the ovary, hypercalcemic type—genetics, new treatment targets, and current management guidelines. Clin Cancer Res 26(15):3908–3917. https://doi.org/10.1158/1078-0432.ccr-19-3797

19. Podwika SE, Jenkins TM, Khokhar JK, Erickson SH, Modesitt SC (2020) Optimal age for genetic cancer predisposition testing in hereditary SMARCA4 Ovarian Cancer Families: How young is too young? Gynecol Oncol Rep 32:100569. https://doi.org/10.1016/j.gore.2020.100569

20. Saunders J, Ingle K, Wang XQ et al (2020) Loss of BRG1 (SMARCA4) immunoexpression in a pediatric non-central nervous system tumor cohort. Pediatr Dev Pathol 23(2):132–138. https://doi.org/10.1177/1093526619869154

21. Heo SH, Kim JW, Shin SS et al (2014) Review of ovarian tumors in children and adolescents: radiologic-pathologic correlation. Radiographics 34(7):2039–2055. https://doi.org/10.1148/rg.347130144

22. Pressey JG, Kelly DR, Hawthorne HT (2013) Successful treatment of preadolescents with small cell carcinoma of the ovary hypercalcemic type. J Pediat Hematol 35(7):24

23. Pejovic T, McCluggage WG, Krieg AJ et al (2019) The dilemma of early preventive oophorectomy in familial small cell carcinoma of the ovary of hypercalcemic type. Gynecol Oncol Rep 28:47–49. https://doi.org/10.1016/j.gore.2019.02.002

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.